Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (4): 313-317.doi: 10.35541/cjd.20201111
• Melanoma·Review • Previous Articles Next Articles
Sha Shanshan1, Li Jun2, Tao Juan1
Received:
2020-11-20
Revised:
2021-01-12
Online:
2021-04-15
Published:
2021-03-31
Contact:
Tao Juan
E-mail:tjhappy@126.com
Supported by:
Sha Shanshan, Li Jun, Tao Juan. Melanoma immunotherapy: difficulties and strategies[J]. Chinese Journal of Dermatology, 2021, 54(4): 313-317.doi:10.35541/cjd.20201111
[1] | Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma[J]. Nat Rev Clin Oncol, 2017,14(8):463⁃482. doi: 10.1038/nrclinonc.2017. 43. |
[2] | Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond[J]. J Invest Dermatol, 2021,141(1):23⁃31. doi: 10.1016/j.jid.2020.03.943. |
[3] | Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor⁃infiltrating immune cells and their therapeutic implications[J]. Cell Mol Immunol, 2020,17(8):807⁃821. doi: 10.1038/s41423⁃020⁃0488⁃6. |
[4] | Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti⁃tumor T cell responses[J]. J Cell Biochem, 2007,102(2):301⁃310. doi: 10.1002/jcb.21473. |
[5] | Davey RJ, van der Westhuizen A, Bowden NA. Metastatic melanoma treatment: combining old and new therapies[J]. Crit Rev Oncol Hematol, 2016,98:242⁃253. doi: 10.1016/j.critrevonc. 2015.11.011. |
[6] | Hamid O, Ismail R, Puzanov I. Intratumoral immunotherapy⁃update 2019[J]. Oncologist, 2020,25(3):e423⁃e438. doi: 10.1634/ theoncologist.2019⁃0438. |
[7] | Rohaan MW, van den Berg JH, Kvistborg P, et al. Adoptive transfer of tumor⁃infiltrating lymphocytes in melanoma: a viable treatment option[J]. J Immunother Cancer, 2018,6(1):102. doi: 10.1186/s40425⁃018⁃0391⁃1. |
[8] | Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline[J]. J Clin Oncol, 2020,38(33):3947⁃3970. doi: 10.1200/JCO.20.00198. |
[9] | Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019,18(3):197⁃218. doi: 10.1038/s41573⁃018⁃0007⁃y. |
[10] | Ayers M, Nebozhyn M, Cristescu R, et al. Molecular profiling of cohorts of tumor samples to guide clinical development of pembrolizumab as monotherapy[J]. Clin Cancer Res, 2019,25(5):1564⁃1573. doi: 10.1158/1078⁃0432.CCR⁃18⁃1316. |
[11] | Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition[J]. Clin Cancer Res, 2016,22(8):1865⁃1874. doi: 10.1158/1078⁃0432.CCR⁃15⁃1507. |
[12] | Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD⁃L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018,554(7693):544⁃548. doi: 10.1038/nature25501. |
[13] | Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies[J]. Nat Rev Cancer, 2016,16(7):447⁃462. doi: 10.1038/nrc.2016.54. |
[14] | Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy[J]. Immunity, 2020,52(1):17⁃35. doi: 10.1016/j.immuni.2019.12.011. |
[15] | Spranger S, Bao R, Gajewski TF. Melanoma⁃intrinsic β⁃catenin signalling prevents anti⁃tumour immunity[J]. Nature, 2015,523(7559):231⁃235. doi: 10.1038/nature14404. |
[16] | Guerra L, Bonetti L, Brenner D. Metabolic modulation of immunity: a new concept in cancer immunotherapy[J]. Cell Rep, 2020,32(1):107848. doi: 10.1016/j.celrep.2020.107848. |
[17] | Warming "cold" melanoma with TLR9 agonists[J]. Cancer Discov, 2018,8(6):670. doi: 10.1158/2159⁃8290.CD⁃ND2018⁃004. |
[18] | O′Sullivan D, Sanin DE, Pearce EJ, et al. Metabolic interventions in the immune response to cancer[J]. Nat Rev Immunol, 2019,19(5):324⁃335. doi: 10.1038/s41577⁃019⁃0140⁃9. |
[19] | Russell L, Peng KW, Russell SJ, et al. Oncolytic viruses: priming time for cancer immunotherapy[J]. BioDrugs, 2019,33(5):485⁃501. doi: 10.1007/s40259⁃019⁃00367⁃0. |
[20] | Duan Q, Zhang H, Zheng J, et al. Turning cold into hot: firing up the tumor microenvironment[J]. Trends Cancer, 2020,6(7):605⁃618. doi: 10.1016/j.trecan.2020.02.022. |
[21] | Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma[J]. Semin Cancer Biol, 2018,52(Pt 2):207⁃215. doi: 10.1016/j.semcancer.2017.09.004. |
[22] | Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer, 2019,19(3):133⁃150. doi: 10.1038/s41568⁃019⁃0116⁃x. |
[23] | Martens A, Wistuba⁃Hamprecht K, Geukes Foppen M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab[J]. Clin Cancer Res, 2016,22(12):2908⁃2918. doi: 10.1158/1078⁃0432.CCR⁃15⁃2412. |
[24] | Cristescu R, Mogg R, Ayers M, et al. Pan⁃tumor genomic biomarkers for PD⁃1 checkpoint blockade⁃based immunotherapy[J]. Science, 2018,362(6411):eaar3593. doi: 10.1126/science.aar3593. |
[25] | O′Donnell JS, Long GV, Scolyer RA, et al. Resistance to PD1/PDL1 checkpoint inhibition[J]. Cancer Treat Rev, 2017,52:71⁃81. doi: 10.1016/j.ctrv.2016.11.007. |
[26] | Gide TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma[J]. Clin Cancer Res, 2018,24(6):1260⁃1270. doi: 10.1158/1078⁃0432.CCR⁃17⁃2267. |
[27] | Egen JG, Ouyang W, Wu LC. Human anti⁃tumor immunity: insights from immunotherapy clinical trials[J]. Immunity, 2020,52(1):36⁃54. doi: 10.1016/j.immuni.2019.12.010. |
[28] | Fankhauser M, Broggi M, Potin L, et al. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma[J]. Sci Transl Med, 2017,9(407):eaal4712. doi: 10.1126/scitranslmed.aal4712. |
[29] | Kalbasi A, Ribas A. Tumour⁃intrinsic resistance to immune checkpoint blockade[J]. Nat Rev Immunol, 2020,20(1):25⁃39. doi: 10.1038/s41577⁃019⁃0218⁃4. |
[30] | Zaretsky JM, Garcia⁃Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD⁃1 blockade in melanoma[J]. N Engl J Med, 2016,375(9):819⁃829. doi: 10. 1056/NEJMoa1604958. |
[31] | Trujillo JA, Luke JJ, Zha Y, et al. Secondary resistance to immunotherapy associated with β⁃catenin pathway activation or PTEN loss in metastatic melanoma[J]. J Immunother Cancer, 2019,7(1):295. doi: 10.1186/s40425⁃019⁃0780⁃0. |
[32] | Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial[J]. JAMA, 2014,312(17):1744⁃1753. doi: 10.1001/jama.2014.13943. |
[33] | Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti⁃PD⁃1 immunotherapy[J]. Cell, 2017,170(6):1109⁃1119.e10. doi: 10.1016/j.cell.2017.08.027. |
[34] | Li M, Yang Y, Wei J, et al. Enhanced chemo⁃immunotherapy against melanoma by inhibition of cholesterol esterification in CD8+ T cells[J]. Nanomedicine, 2018,14(8):2541⁃2550. doi: 10.1016/j.nano.2018.08.008. |
[35] | Wanderley CW, Colón DF, Luiz J, et al. Paclitaxel reduces tumor growth by reprogramming tumor⁃associated macrophages to an M1 profile in a TLR4⁃dependent manner[J]. Cancer Res, 2018,78(20):5891⁃5900. doi: 10.1158/0008⁃5472.CAN⁃17⁃3480. |
[36] | Williams NL, Wuthrick EJ, Kim H, et al. Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases[J]. Int J Radiat Oncol Biol Phys, 2017,99(1):22⁃30. doi: 10.1016/j.ijrobp.2017.05.028. |
[37] | Nass SJ, Rothenberg ML, Pentz R, et al. Accelerating anticancer drug development ⁃ opportunities and trade⁃offs[J]. Nat Rev Clin Oncol, 2018,15(12):777⁃786. doi: 10.1038/s41571⁃018⁃0102⁃3. |
[38] | Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials[J]. Clin Pharmacol Ther, 2017,102(6):934⁃941. doi: 10.1002/cpt.814. |
[39] | Wang DY, Johnson DB, Davis EJ. Toxicities associated with PD⁃1/PD⁃L1 blockade[J]. Cancer J, 2018,24(1):36⁃40. doi: 10. 1097/PPO.0000000000000296. |
[40] | Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti⁃PD⁃1 in patients with immune⁃related adverse events (irAEs) during combined anti⁃CTLA⁃4 and anti⁃PD1 in metastatic melanoma[J]. Ann Oncol, 2018,29(1):250⁃255. doi: 10.1093/annonc/mdx642. |
[41] | Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine[J]. Nat Rev Immunol, 2020,20(5):321⁃334. doi: 10.1038/s41577⁃019⁃0269⁃6. |
[42] | Phuengkham H, Ren L, Shin IW, et al. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy[J]. Adv Mater, 2019,31(34):e1803322. doi: 10.1002/adma.201803 322. |
[43] | Shi Y, Lammers T. Combining nanomedicine and immunotherapy[J]. Acc Chem Res, 2019, 52(6):1543⁃1554. doi: 10.1021/acs.accounts.9b00148. |
[44] | Xie J, Yang C, Liu Q, et al. Encapsulation of hydrophilic and hydrophobic peptides into hollow mesoporous silica nanoparticles for enhancement of antitumor immune response[J/OL]. Small,2017,13(40):1701741. https://onlinelibrary.wiley.com/doi/full/10.1002/smll.201701741. doi: 10.1002/smll.201701741. |
[45] | Dong L, Li Y, Li Z, et al. Au nanocage⁃strengthened dissolving microneedles for chemo⁃photothermal combined therapy of superficial skin tumors[J]. ACS Appl Mater Interfaces, 2018,10(11):9247⁃9256. doi: 10.1021/acsami.7b18293. |
[1] | Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478. |
[2] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482. |
[3] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[4] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
[5] | Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429. |
[6] | Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378. |
[7] | Chen Zhu, Dong Liping, Xiao Fengli, . Research progress in atopic diseases from the perspective of metabolomics [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220366-e20220366. |
[8] | Yao Manxue, Zhou Naihui. Stevens-Johnson syndrome/toxic epidermal necrolysis associated with programmed death-1/programmed death-ligand 1 inhibitors [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220644-e20220644. |
[9] | Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220795-e20220795. |
[10] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
[11] | Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of disease progression and influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 0(2): 20230167-e20230167. |
[12] | Pan Ruoxin, Gu Duoduo, Zhang Yue, Li Min, Tao Meng, Xu Yang. Metabolomics in rosacea [J]. Chinese Journal of Dermatology, 2024, 57(2): 178-181. |
[13] | China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis (2024) [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108. |
[14] | Dong Dong, Liu Tianyi. Cell metabolism and metastasis of cutaneous malignant melanoma [J]. Chinese Journal of Dermatology, 2023, 56(9): 878-881. |
[15] | Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723. |
|